Dermal Fillers Surgery

 http://t3.gstatic.com/images?q=tbn:ANd9GcRfJI_oBLJPZ7RlpfJnO_GVYwGDPGKrsUwRyY5INP4mzP_xh1xIeBAwbjU

 As your skin ages and loses volume, wrinkles and folds can form on your face and neck. Dermal filler injections are among the fastest-growing nonsurgical ways to restore your youthful appearance.

Most dermal filler patients are age 35 or older. But people of any age can have dermal filler injections to correct scarring, pitting, or other facial depressions from acne, injuries, or other conditions.
Injectable fillers can reduce:
  • Wrinkles
  • Folds (sometimes called smile lines or laugh lines) that run from the nose to the corners of the mouth (nasolabial folds)
  • Marionette lines from the corners of the mouth to the chin
  • Vertical lip lines
  • Thinning lips
  • A shrinking lip border
  • Cheek depressions
  • Acne scars
  • Hollows under the eyes
  • Sagging eyebrows
  • Facial depressions
  • Jowls
The gifted plastic surgeons at Summit Medical Group are experts with the following cosmetic fillers:
  • Restylane®
  • Juvederm®
  • Sculptra™
  • Radiesse®
  • Evolence®
These facial fillers are safe, FDA-approved, and provide natural results.

The procedure

 Dermal injections are given with a very fine needle. The treatment usually only takes 15 to 30 minutes. Most patients experience little or no discomfort during or after the procedure. Complications with dermal fillers are very rare.
Restylane and Juvederm are smooth gels made from plants. Both fillers are similar to a substance (hyaluronic acid) that naturally occurs in your body. The fillers immediately soften lines and wrinkles.
Sculptra is a synthetic, biodegradable substance made from fruit acids. It stimulates your body to produce new collagen and gradually increases skin thickness—a process that helps fill in lines and wrinkles. Like Restylane and Juvederm, complications with Sculptra are rare.
Radiesse is a calcium-based substance that stimulates your body to produce collagen. It reduces the appearance of facial lines, creases, wrinkles, and folds. It also can be used to shape (contour) the face.
Evolence is made from a natural collagen. It can be used to contour the face. Evolence is excellent for filling in lines, creases, wrinkles, and folds.
Depending on your goals, your plastic surgeon might recommend more than 1 type of filler to help you achieve the best possible result.
The procedure can be carried out in about 30-60 minutes.

The dermal filler that you and the surgeon choose may depend on the results you require and the area being filled (for example, delicate lines or deep furrows), as well as your preference regarding advantages and disadvantages. Common brands include Collagen – made from bovine tissue protein and Restylane - which contains a non-animal stabilised hyaluronic acid (a substance which is also naturally produced in the body).

A topical anaesthetic cream may be applied to reduce discomfort, then the surgeon or practitioner will inject the filler into the site to be treated to plump out the skin, repeating as necessary on other areas. It will be gently massaged once it has been injected into the site. The filler then remains in the skin where it binds water to produce a lift and give firmness to the treated areas.

The procedure is minimally invasive with mild discomfort and won’t leave scars.

The outcome

Following the procedure, there may be some redness in the treated areas, though this is usually minimal. Your face may be a little swollen and tender for a short period.

Normally, patients can leave the clinic a few minutes after the procedure. You can return to work the same day and resume most activities within four hours. The treatment starts to work in about 3-5 days, with the greatest effect seen after about 1-2 weeks. Make-up may be applied immediately afterwards.

Lines and wrinkles treated should appear smoother and softer, giving a more ‘youthful’ appearance to the face. The effects are not permanent but should last for around 3-9 months.

The risks

Complications particular to dermal fillers include a risk of allergic reaction to the filler, compounded by the fact that once injected, the treatment cannot be reversed until the effects have worn off. Allergy tests may be necessary to reduce the chance of this occurring.

If you experience cold sores, then there may be a recurrence of them after treatment, although the chance of this can be minimised by the use of antiviral medicines. There is a slight risk of longer-lasting bruising to the treated area.

Rare side effects may include tissue hardening and lumps or bumps around the area.

The costs

In the UK, expect to pay from around £200 to £1,000 for one treatment, depending on the product used and how large the area to be treated is. Abroad, expect to pay from around £285 to £950 (Belgium).

The availability

Dermal filler procedures are widely available at private cosmetic surgery clinics and specialist skincare clinics within the UK and abroad.

The popularity

Dermal fillers are a popular non-invasive type of procedure amongst women and men who would like to smooth out lines and wrinkles, or correct imperfections on their face, with what is seen as a relatively safe and non-surgical procedure.

Recovery and Results Results

Results from dermal fillers are immediate and often improve over time. The effects usually last 6 months to 2 years. After a few treatments, some patients need less of the fillers and their results can last longer. Sculptra, Evolence, and Radiesse provide longer-lasting results compared with many other dermal fillers.
No down time is needed to recover after treatment with dermal fillers. Most side effects such as redness or tenderness at the injection sites, firmness, swelling, lumps/bumps, itching, bruising, or discoloration are mild and last less than 5 days.
After dermal filler injections, patients should avoid:
  • Getting too much sun
  • Drinking alcohol
  • Exercising for 24 hours (to prevent unnecessary bruising)
  • Cold outdoor activities
 http://t2.gstatic.com/images?q=tbn:ANd9GcSOgOhdlTZ9EEXouCndTBPMrh_RWcRfnD1t1ZYjSq4FJxrq7thwFOvxdH3Rhttp://t0.gstatic.com/images?q=tbn:ANd9GcSo2g8eCxTNTEFR-cUHaFc9krYFvjdgOpGuuivyUophzENpA4v8BdvX3_Uhttp://t1.gstatic.com/images?q=tbn:ANd9GcRYyluyc1vLhvJ1v6vArrXCoV9OglY1hI6lktmEflBkQEuB8RCH3wrlry9ikQhttp://t2.gstatic.com/images?q=tbn:ANd9GcQwnQymtnQiYaYqogza1adqGYpKzbdkEbPsk4koJQvOLdOWdkQ9SEWkvHkgxAhttp://t1.gstatic.com/images?q=tbn:ANd9GcSx622zMgCj6nTV91RpBYlSgflrBJDY-Mo7KY_4NlYwvs8LJFO4TPKZBfqlhttp://t1.gstatic.com/images?q=tbn:ANd9GcTYFuyOaPmkAGaS0FkIfVeQS2myxc2fptAgpDy2lMiaNESfW9zH35nL3szr6Qhttp://t0.gstatic.com/images?q=tbn:ANd9GcTCsWWXp2BBkGnoMp33qNASLxB1sWBNOWO9gMHVpb8AvjmrHatexDp-Xw0shttp://t2.gstatic.com/images?q=tbn:ANd9GcTNucmvGqHSrqM1pA4F_dGj1jn1bW5gKWTOoQ8E5uiSLV7OLKQfxPvp_BEhttp://t3.gstatic.com/images?q=tbn:ANd9GcRx5bcsapwFUQQRL2TnLfJ-QyIm_k-mFQkTjz49anE610EPv2n9aAhttp://t1.gstatic.com/images?q=tbn:ANd9GcS_wQeHTiGGP6_Pyf5_X7oTxSqP0YaW7SyyitsyAbmq8w7UvczQDNMWSgq4Bwhttp://t3.gstatic.com/images?q=tbn:ANd9GcQEw1nrGRUVImzFabsS6VHtH8uULMXxq4yDLozz05k8M50ShVaQHXpCRkeVEAhttp://t3.gstatic.com/images?q=tbn:ANd9GcQ1_IJCQbCU9c5qiB57JiAmKqNjldUvf2kzCgffTHeHhEb-zBUbNnxgpS78LAhttp://t2.gstatic.com/images?q=tbn:ANd9GcTHrIHo9_A8skQMOV9FgVi0ggoapD_zxp2yVX_k6l1EbvppGF69QvZy1tEhttp://t0.gstatic.com/images?q=tbn:ANd9GcTh8kAGW1izwVTm8sF9In55auKkMAI3ysN0RC7wP6I9Kie9o4sZhttp://t0.gstatic.com/images?q=tbn:ANd9GcRamrhUbg7gHO98FXyaaEr8rk1g2eZ0Ae0XH1toSFbAMbUMzV1pSW1lQMazkAhttp://t3.gstatic.com/images?q=tbn:ANd9GcQcNBtv2sxLMplqoypSvm0b2dZkU8d-FhCWdEn5Gb-FCmoGRq_D9hbKJXvyGghttp://t0.gstatic.com/images?q=tbn:ANd9GcT4vwxm0ARG6xAYWDZvn73x-qj_7W1vP7CJpxa7EoHy28LeE5z1ZZrW6BL7mQhttp://t2.gstatic.com/images?q=tbn:ANd9GcRMHv7zRkeH5iuD2UQ-Ut6uXIj2QAXkpAePZogzBegSquU3-NTejZR8fVt1http://t0.gstatic.com/images?q=tbn:ANd9GcRHwpNm9u-mSpMXuaSJOFUhzCIOFteFuTryv713uWRXEyPpv3gFUxG7Apwhttp://t3.gstatic.com/images?q=tbn:ANd9GcSitNeOlKIV5hL8-UlCcGLoC5eruhhJz61sW55hBHjUZvFe91mtW4d5KMDAcQhttp://t2.gstatic.com/images?q=tbn:ANd9GcSKizDqGtZbfaPdOT-kbcqQYtBJvfIpHy0ctZLdS7ulKOivQM4Qhttp://t3.gstatic.com/images?q=tbn:ANd9GcQCevBAh87UFIx2WaLYR0UwKxh_rFB_RhMK83Gqdp9lgGuWlAugiwhttp://t2.gstatic.com/images?q=tbn:ANd9GcQKxkwowl20zWx9vu1K3a-v685mFSPymendKeKPNx3w8mzKe-SBUVjSSZ2Zhttp://t3.gstatic.com/images?q=tbn:ANd9GcSPJIIL92SATLlSM4LNLmCMSrxGQwEPtDBSL2MxLm4iqdYgC2XMhttp://t3.gstatic.com/images?q=tbn:ANd9GcRZwB3rXk9fASq2nCxKP7DT5E736aM-5vltyjaM__jngXfoR9GMmwhttp://t1.gstatic.com/images?q=tbn:ANd9GcS4WP9cA4O7Ndlq-3-xKnEsmml0tNoBnj3s0S2wwV4bRzzfaDri-whttp://t0.gstatic.com/images?q=tbn:ANd9GcTQnZ5xhNvTLHx5Vx8rs3tunUhpPk3pqMkGSRzuQC5ueVaxRTFnBDysFOEhttp://t2.gstatic.com/images?q=tbn:ANd9GcTl3_NaRcerECmkKT1JoPFmEm-S8H_7wAi6f3xQTZgT3s_vGKeT32jC6IjH0Adata:image/jpg;base64,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http://t0.gstatic.com/images?q=tbn:ANd9GcRwT-7EbtQwtbE9IvORyBoJR5vZqCCfcPyLjqGjJtgqX5g6AmlqQHRZS8Yhttp://t0.gstatic.com/images?q=tbn:ANd9GcTzMcMSo07guc1C63NRi6OaoXyjdssVGWC3JbA85hT9huPT08bPDAhttp://t0.gstatic.com/images?q=tbn:ANd9GcTbKd9RW32eC05ezNi4KSr37ujYwn2if_NsxqP1jH1bVdUwePxh13TYFHZghttp://t3.gstatic.com/images?q=tbn:ANd9GcRxYs12s3Lwwi9wCKbys9KzUxuwX6ft5nAc5b4NjSyH1YApxhDlYDfCMFQrBQ

0 comments: